Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies
Background Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities. Objective The objective of this study...
Gespeichert in:
| Veröffentlicht in: | CNS drugs 2024-10, Vol.38 (10), p.819-825 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 825 |
|---|---|
| container_issue | 10 |
| container_start_page | 819 |
| container_title | CNS drugs |
| container_volume | 38 |
| creator | Para, Davide Camponovo, Chiara Riccitelli, Gianna Carla Mallucci, Giulia Maino, Paolo Mondini Trissino da Lodi, Camilla Saudina, Demurtas Trimboli, Pierpaolo Gobbi, Claudio Zecca, Chiara |
| description | Background
Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities.
Objective
The objective of this study was to explore bone mineral density abnormalities in a cohort of migraine patients treated with anti-CGRPs.
Methods
This was a single-center, cross-sectional, cohort study including migraine patients who underwent a densitometry assessment during anti-CGRP treatment. We assessed the frequency of osteopenia or osteoporosis (OSTEO+ status), defined as a bone mineral density T-score of −1 to −2.5, and |
| doi_str_mv | 10.1007/s40263-024-01104-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3096280503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3106351143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-b88dd29e0e7311b056eb45613dad44b0fc338e88f86c2528c2f2046fb488bf1d3</originalsourceid><addsrcrecordid>eNp9kU9vFCEYh4mxsbX1C3gwJF68UF_-DMMc11Fbk27aVD14mjDMOyvNLFSYbdKP4LeW3a2a9NALEHh-PwgPIa85nHKA-n1WILRkIBQDzqGMz8gR53XDeCPV891asBpUfUhe5nwDAEpq_YIcyobXqlbVEfm9yBlzXmOYaRzphxiQLn3AZCf6EUP28z29vMNEOf2BNlEfqKVtijmzr-hmH0MB2_gzpl1-6VfJlji9srMvnZleo0N_58OKLsLsWXt2fUWXMUQ37aLbzT4OHvMJORjtlPHVw3xMvn_-9K09ZxeXZ1_axQVzEmBmvTHDIBoErCXnPVQae1VpLgc7KNXD6KQ0aMxotBOVME6MApQee2VMP_JBHpN3-97bFH9tMM_d2meH02QDxk3uJDRaGKhAFvTtI_QmblJ5dqE4aFlxrraU2FNu-y0Jx-42-bVN9x2Hbiuq24vqiqhuJ6qDEnrzUL3p1zj8i_w1UwC5B3I5CitM_-9-ovYPDlOdSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106351143</pqid></control><display><type>article</type><title>Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Para, Davide ; Camponovo, Chiara ; Riccitelli, Gianna Carla ; Mallucci, Giulia ; Maino, Paolo ; Mondini Trissino da Lodi, Camilla ; Saudina, Demurtas ; Trimboli, Pierpaolo ; Gobbi, Claudio ; Zecca, Chiara</creator><creatorcontrib>Para, Davide ; Camponovo, Chiara ; Riccitelli, Gianna Carla ; Mallucci, Giulia ; Maino, Paolo ; Mondini Trissino da Lodi, Camilla ; Saudina, Demurtas ; Trimboli, Pierpaolo ; Gobbi, Claudio ; Zecca, Chiara</creatorcontrib><description>Background
Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities.
Objective
The objective of this study was to explore bone mineral density abnormalities in a cohort of migraine patients treated with anti-CGRPs.
Methods
This was a single-center, cross-sectional, cohort study including migraine patients who underwent a densitometry assessment during anti-CGRP treatment. We assessed the frequency of osteopenia or osteoporosis (OSTEO+ status), defined as a bone mineral density T-score of −1 to −2.5, and <−2.5 standard deviations from the young female adult mean, respectively. Additionally, the association of OSTEO+ status with anti-CGRP treatment duration and primary osteoporosis’ risk factors was investigated using logistic regression models.
Results
Data from 51 patients (43 female, mean age 46 ± 13.9 years) were evaluated. The mean duration of anti-CGRP treatment was 15.7 (±11.8) months. Twenty-seven patients (53%) were OSTEO+ (
n
= 22 osteopenia;
n
= 5 osteoporosis). In the final model, menopause [odds ratio 11.641 (95% confidence interval 1.486–91.197),
p
= 0.019] and anti-seizure drug use [odds ratio 12.825 (95% confidence interval 1.162–141.569),
p
= 0.037] were associated with OSTEO+ status.
Conclusions
In our cohort of migraine patients, no evidence of an association between anti-CGRP treatment duration and an increasing risk of bone mineral density abnormalities was found. However, these findings are preliminary and necessitate further longitudinal research with larger cohorts and extended follow-up to be validated.</description><identifier>ISSN: 1172-7047</identifier><identifier>ISSN: 1179-1934</identifier><identifier>EISSN: 1179-1934</identifier><identifier>DOI: 10.1007/s40263-024-01104-0</identifier><identifier>PMID: 39174745</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Body mass index ; Bone density ; Bone Density - drug effects ; Bone Diseases, Metabolic - epidemiology ; Bone mineral density ; Calcitonin ; Calcitonin gene-related peptide ; Calcitonin Gene-Related Peptide - immunology ; Cohort analysis ; Cohort Studies ; Convulsions & seizures ; Cross-Sectional Studies ; Densitometry ; Drugs ; Female ; Females ; Fractures ; Headache ; Humans ; Male ; Medicine ; Medicine & Public Health ; Menopause ; Metabolic disorders ; Middle Aged ; Migraine ; Migraine Disorders - drug therapy ; Monoclonal antibodies ; Neurology ; Neurosciences ; Original Research Article ; Osteopenia ; Osteoporosis ; Osteoporosis - drug therapy ; Patients ; Peptides ; Pharmacotherapy ; Prevention ; Psychiatry ; Psychopharmacology ; Regression analysis ; Risk Factors ; Seizures ; Side effects ; Software ; Standard deviation</subject><ispartof>CNS drugs, 2024-10, Vol.38 (10), p.819-825</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>Copyright Springer Nature B.V. Oct 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-b88dd29e0e7311b056eb45613dad44b0fc338e88f86c2528c2f2046fb488bf1d3</cites><orcidid>0000-0002-9990-3431 ; 0000-0002-7554-0664 ; 0000-0002-0678-3240 ; 0000-0002-1202-5534 ; 0000-0002-2125-4937 ; 0000-0002-0031-9594 ; 0000-0002-5898-145X ; 0000-0001-8586-9925</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40263-024-01104-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40263-024-01104-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39174745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Para, Davide</creatorcontrib><creatorcontrib>Camponovo, Chiara</creatorcontrib><creatorcontrib>Riccitelli, Gianna Carla</creatorcontrib><creatorcontrib>Mallucci, Giulia</creatorcontrib><creatorcontrib>Maino, Paolo</creatorcontrib><creatorcontrib>Mondini Trissino da Lodi, Camilla</creatorcontrib><creatorcontrib>Saudina, Demurtas</creatorcontrib><creatorcontrib>Trimboli, Pierpaolo</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Zecca, Chiara</creatorcontrib><title>Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies</title><title>CNS drugs</title><addtitle>CNS Drugs</addtitle><addtitle>CNS Drugs</addtitle><description>Background
Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities.
Objective
The objective of this study was to explore bone mineral density abnormalities in a cohort of migraine patients treated with anti-CGRPs.
Methods
This was a single-center, cross-sectional, cohort study including migraine patients who underwent a densitometry assessment during anti-CGRP treatment. We assessed the frequency of osteopenia or osteoporosis (OSTEO+ status), defined as a bone mineral density T-score of −1 to −2.5, and <−2.5 standard deviations from the young female adult mean, respectively. Additionally, the association of OSTEO+ status with anti-CGRP treatment duration and primary osteoporosis’ risk factors was investigated using logistic regression models.
Results
Data from 51 patients (43 female, mean age 46 ± 13.9 years) were evaluated. The mean duration of anti-CGRP treatment was 15.7 (±11.8) months. Twenty-seven patients (53%) were OSTEO+ (
n
= 22 osteopenia;
n
= 5 osteoporosis). In the final model, menopause [odds ratio 11.641 (95% confidence interval 1.486–91.197),
p
= 0.019] and anti-seizure drug use [odds ratio 12.825 (95% confidence interval 1.162–141.569),
p
= 0.037] were associated with OSTEO+ status.
Conclusions
In our cohort of migraine patients, no evidence of an association between anti-CGRP treatment duration and an increasing risk of bone mineral density abnormalities was found. However, these findings are preliminary and necessitate further longitudinal research with larger cohorts and extended follow-up to be validated.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Body mass index</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Diseases, Metabolic - epidemiology</subject><subject>Bone mineral density</subject><subject>Calcitonin</subject><subject>Calcitonin gene-related peptide</subject><subject>Calcitonin Gene-Related Peptide - immunology</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Convulsions & seizures</subject><subject>Cross-Sectional Studies</subject><subject>Densitometry</subject><subject>Drugs</subject><subject>Female</subject><subject>Females</subject><subject>Fractures</subject><subject>Headache</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Monoclonal antibodies</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Original Research Article</subject><subject>Osteopenia</subject><subject>Osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Patients</subject><subject>Peptides</subject><subject>Pharmacotherapy</subject><subject>Prevention</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Regression analysis</subject><subject>Risk Factors</subject><subject>Seizures</subject><subject>Side effects</subject><subject>Software</subject><subject>Standard deviation</subject><issn>1172-7047</issn><issn>1179-1934</issn><issn>1179-1934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9vFCEYh4mxsbX1C3gwJF68UF_-DMMc11Fbk27aVD14mjDMOyvNLFSYbdKP4LeW3a2a9NALEHh-PwgPIa85nHKA-n1WILRkIBQDzqGMz8gR53XDeCPV891asBpUfUhe5nwDAEpq_YIcyobXqlbVEfm9yBlzXmOYaRzphxiQLn3AZCf6EUP28z29vMNEOf2BNlEfqKVtijmzr-hmH0MB2_gzpl1-6VfJlji9srMvnZleo0N_58OKLsLsWXt2fUWXMUQ37aLbzT4OHvMJORjtlPHVw3xMvn_-9K09ZxeXZ1_axQVzEmBmvTHDIBoErCXnPVQae1VpLgc7KNXD6KQ0aMxotBOVME6MApQee2VMP_JBHpN3-97bFH9tMM_d2meH02QDxk3uJDRaGKhAFvTtI_QmblJ5dqE4aFlxrraU2FNu-y0Jx-42-bVN9x2Hbiuq24vqiqhuJ6qDEnrzUL3p1zj8i_w1UwC5B3I5CitM_-9-ovYPDlOdSA</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Para, Davide</creator><creator>Camponovo, Chiara</creator><creator>Riccitelli, Gianna Carla</creator><creator>Mallucci, Giulia</creator><creator>Maino, Paolo</creator><creator>Mondini Trissino da Lodi, Camilla</creator><creator>Saudina, Demurtas</creator><creator>Trimboli, Pierpaolo</creator><creator>Gobbi, Claudio</creator><creator>Zecca, Chiara</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9990-3431</orcidid><orcidid>https://orcid.org/0000-0002-7554-0664</orcidid><orcidid>https://orcid.org/0000-0002-0678-3240</orcidid><orcidid>https://orcid.org/0000-0002-1202-5534</orcidid><orcidid>https://orcid.org/0000-0002-2125-4937</orcidid><orcidid>https://orcid.org/0000-0002-0031-9594</orcidid><orcidid>https://orcid.org/0000-0002-5898-145X</orcidid><orcidid>https://orcid.org/0000-0001-8586-9925</orcidid></search><sort><creationdate>20241001</creationdate><title>Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies</title><author>Para, Davide ; Camponovo, Chiara ; Riccitelli, Gianna Carla ; Mallucci, Giulia ; Maino, Paolo ; Mondini Trissino da Lodi, Camilla ; Saudina, Demurtas ; Trimboli, Pierpaolo ; Gobbi, Claudio ; Zecca, Chiara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-b88dd29e0e7311b056eb45613dad44b0fc338e88f86c2528c2f2046fb488bf1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Body mass index</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Diseases, Metabolic - epidemiology</topic><topic>Bone mineral density</topic><topic>Calcitonin</topic><topic>Calcitonin gene-related peptide</topic><topic>Calcitonin Gene-Related Peptide - immunology</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Convulsions & seizures</topic><topic>Cross-Sectional Studies</topic><topic>Densitometry</topic><topic>Drugs</topic><topic>Female</topic><topic>Females</topic><topic>Fractures</topic><topic>Headache</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Monoclonal antibodies</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Original Research Article</topic><topic>Osteopenia</topic><topic>Osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Patients</topic><topic>Peptides</topic><topic>Pharmacotherapy</topic><topic>Prevention</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Regression analysis</topic><topic>Risk Factors</topic><topic>Seizures</topic><topic>Side effects</topic><topic>Software</topic><topic>Standard deviation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Para, Davide</creatorcontrib><creatorcontrib>Camponovo, Chiara</creatorcontrib><creatorcontrib>Riccitelli, Gianna Carla</creatorcontrib><creatorcontrib>Mallucci, Giulia</creatorcontrib><creatorcontrib>Maino, Paolo</creatorcontrib><creatorcontrib>Mondini Trissino da Lodi, Camilla</creatorcontrib><creatorcontrib>Saudina, Demurtas</creatorcontrib><creatorcontrib>Trimboli, Pierpaolo</creatorcontrib><creatorcontrib>Gobbi, Claudio</creatorcontrib><creatorcontrib>Zecca, Chiara</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>CNS drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Para, Davide</au><au>Camponovo, Chiara</au><au>Riccitelli, Gianna Carla</au><au>Mallucci, Giulia</au><au>Maino, Paolo</au><au>Mondini Trissino da Lodi, Camilla</au><au>Saudina, Demurtas</au><au>Trimboli, Pierpaolo</au><au>Gobbi, Claudio</au><au>Zecca, Chiara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies</atitle><jtitle>CNS drugs</jtitle><stitle>CNS Drugs</stitle><addtitle>CNS Drugs</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>38</volume><issue>10</issue><spage>819</spage><epage>825</epage><pages>819-825</pages><issn>1172-7047</issn><issn>1179-1934</issn><eissn>1179-1934</eissn><abstract>Background
Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities.
Objective
The objective of this study was to explore bone mineral density abnormalities in a cohort of migraine patients treated with anti-CGRPs.
Methods
This was a single-center, cross-sectional, cohort study including migraine patients who underwent a densitometry assessment during anti-CGRP treatment. We assessed the frequency of osteopenia or osteoporosis (OSTEO+ status), defined as a bone mineral density T-score of −1 to −2.5, and <−2.5 standard deviations from the young female adult mean, respectively. Additionally, the association of OSTEO+ status with anti-CGRP treatment duration and primary osteoporosis’ risk factors was investigated using logistic regression models.
Results
Data from 51 patients (43 female, mean age 46 ± 13.9 years) were evaluated. The mean duration of anti-CGRP treatment was 15.7 (±11.8) months. Twenty-seven patients (53%) were OSTEO+ (
n
= 22 osteopenia;
n
= 5 osteoporosis). In the final model, menopause [odds ratio 11.641 (95% confidence interval 1.486–91.197),
p
= 0.019] and anti-seizure drug use [odds ratio 12.825 (95% confidence interval 1.162–141.569),
p
= 0.037] were associated with OSTEO+ status.
Conclusions
In our cohort of migraine patients, no evidence of an association between anti-CGRP treatment duration and an increasing risk of bone mineral density abnormalities was found. However, these findings are preliminary and necessitate further longitudinal research with larger cohorts and extended follow-up to be validated.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39174745</pmid><doi>10.1007/s40263-024-01104-0</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9990-3431</orcidid><orcidid>https://orcid.org/0000-0002-7554-0664</orcidid><orcidid>https://orcid.org/0000-0002-0678-3240</orcidid><orcidid>https://orcid.org/0000-0002-1202-5534</orcidid><orcidid>https://orcid.org/0000-0002-2125-4937</orcidid><orcidid>https://orcid.org/0000-0002-0031-9594</orcidid><orcidid>https://orcid.org/0000-0002-5898-145X</orcidid><orcidid>https://orcid.org/0000-0001-8586-9925</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1172-7047 |
| ispartof | CNS drugs, 2024-10, Vol.38 (10), p.819-825 |
| issn | 1172-7047 1179-1934 1179-1934 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3096280503 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Body mass index Bone density Bone Density - drug effects Bone Diseases, Metabolic - epidemiology Bone mineral density Calcitonin Calcitonin gene-related peptide Calcitonin Gene-Related Peptide - immunology Cohort analysis Cohort Studies Convulsions & seizures Cross-Sectional Studies Densitometry Drugs Female Females Fractures Headache Humans Male Medicine Medicine & Public Health Menopause Metabolic disorders Middle Aged Migraine Migraine Disorders - drug therapy Monoclonal antibodies Neurology Neurosciences Original Research Article Osteopenia Osteoporosis Osteoporosis - drug therapy Patients Peptides Pharmacotherapy Prevention Psychiatry Psychopharmacology Regression analysis Risk Factors Seizures Side effects Software Standard deviation |
| title | Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A43%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Bone%20Mineral%20Density%20Over%201%20Year%20in%20a%20Cross-Sectional%20Cohort%20of%20Migraine%20Patients%20Receiving%20Anti-CGRP%20Monoclonal%20Antibodies&rft.jtitle=CNS%20drugs&rft.au=Para,%20Davide&rft.date=2024-10-01&rft.volume=38&rft.issue=10&rft.spage=819&rft.epage=825&rft.pages=819-825&rft.issn=1172-7047&rft.eissn=1179-1934&rft_id=info:doi/10.1007/s40263-024-01104-0&rft_dat=%3Cproquest_cross%3E3106351143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3106351143&rft_id=info:pmid/39174745&rfr_iscdi=true |